Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

AVDL Avadel Pharmaceuticals PLC

11,17

0,02 (0,18%)

28 Nov 2024 - Geschlossen

Verzögert um 15 Minuten

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
Von Okt 2024 bis Nov 2024

Click Here for more Avadel Pharmaceuticals Charts.

Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
Von Nov 2023 bis Nov 2024

Click Here for more Avadel Pharmaceuticals Charts.

News Avadel Pharmaceuticals PLC

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Donnerstag 14 November 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Donnerstag 14 November 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Mittwoch 13 November 2024 (2 Wochen vor) • Edgar (US Regulatory)

Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Mittwoch 13 November 2024 (2 Wochen vor) • GlobeNewswire Inc.

Form 8-K - Current report
Dienstag 12 November 2024 (2 Wochen vor) • Edgar (US Regulatory)

Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Dienstag 12 November 2024 (2 Wochen vor) • GlobeNewswire Inc.

Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12
Montag 4 November 2024 (3 Wochen vor) • GlobeNewswire Inc.

Form 8-K - Current report
Donnerstag 31 Oktober 2024 (4 Wochen vor) • Edgar (US Regulatory)

Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation
Donnerstag 31 Oktober 2024 (4 Wochen vor) • GlobeNewswire Inc.

Avadel Pharmaceuticals and nference Announce Publication of Real-World Data in Sleep Advances
Donnerstag 24 Oktober 2024 (1 Monat vor) • GlobeNewswire Inc.

Form 8-K - Current report
Donnerstag 17 Oktober 2024 (1 Monat vor) • Edgar (US Regulatory)

Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy
Donnerstag 17 Oktober 2024 (1 Monat vor) • GlobeNewswire Inc.

Weitere Avadel Pharmaceuticals PLC News-Artikel

Limitless X (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen